Trials of the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab (Avastin©) in NF2 patients have demonstrated a reduction of VS growth rate [35] and regression in some cases [36], but there is variation in treatment results, with reported tumour response rates of 40–60% [35,36,37]. Here, VEGFA is linked to neoplasm.